On March 3, the NMPA website showed that the hexaminolevulinate hydrochloride ointment photodynamic therapy system for the cervix submitted by Asieris had been approved for marketing. It is intended for the treatment of histologically confirmed high-grade squamous intraepithelial lesions of the cervix in women aged 18 years and older, excluding carcinoma in situ.
The hexaminolevulinate hydrochloride ointment cervical photodynamic therapy system, APL-1702, is a globally first-in-class and first-launched-in-China photodynamic therapy product. It consists of hexaminolevulinate hydrochloride ointment and a single-use cervical photodynamic treatment light, achieving a breakthrough treatment model through innovative local drug delivery and an intravaginal cold light source design:
Convenient outpatient treatment with “treat and leave”: with its integrated drug-device design, the procedure is performed by a gynecologist in an outpatient setting without anesthesia, reducing the single treatment visit to less than 10 minutes. After placement, patients can immediately resume normal work and daily life, do not need to wait in the hospital, and can remove the device themselves after treatment is completed.
Cold light technology improves treatment comfort: the innovative cold light source design used in APL-1702 keeps tissue temperature in the treatment area below 42 degrees Celsius. Clinical data showed that 97% of patients reported no pain in the cervical treatment area and no cervical structural injury was recorded, avoiding the tissue thermal damage that may occur with traditional photodynamic therapy, reducing local irritation, and improving treatment comfort.
As a non-surgical therapeutic approach, photodynamic therapy has been explored in gynecology for many years. At present, it has been used domestically and internationally in the treatment of multiple diseases, including condyloma acuminatum, acne, basal cell carcinoma, and melanoma. However, for a long time, there has been a lack of rigorously designed, large-scale prospective Phase III randomized controlled trials to validate its efficacy and safety in cervical HSIL.
Against this background, Asieris initiated a randomized, double-blind, prospective, placebo-controlled, multicenter Phase III clinical study to evaluate the efficacy and safety of APL-1702 in cervical high-grade squamous intraepithelial lesions. The primary endpoint was the proportion of subjects who achieved response. Response was defined as normal histopathology, or low-grade squamous intraepithelial lesion with clearance of baseline HPV.
This is also the world’s first completed prospective, randomized, double-blind, placebo-controlled, international multicenter Phase III trial of a photodynamic therapy regimen in the field of cervical HSIL.
The relevant clinical data have been published in the international journal Med. The study results showed the following:
At six months after the first treatment, the pathologic regression rate, defined as the proportion of subjects whose histopathology regressed to CIN1 or normal, was significantly higher in the APL-1702 group than in the placebo group, at 47.0% versus 29.5%, p<0.001.
At six months after the first treatment, the histopathologic improvement rates, defined as CIN2 regressing to CIN1 or normal and CIN3 regressing to CIN2, CIN1, or normal, were 53.8% and 36.4% in the APL-1702 and placebo groups, respectively, p=0.001.
The clearance rate of high-risk HPV was 28.0% in the APL-1702 group and 19.8% in the placebo group, p=0.086. For the most oncogenic HPV16/18 subtypes, the clearance rate in the APL-1702 group was 103.90% higher than that of the control group, at 31.4% versus 15.4%, p=0.011.
In stratified analyses by age, HPV status, region, and lesion coverage area, the APL-1702 group also showed better response rate, histopathologic regression rate, and HPV clearance rate than the control group.
In terms of safety, the incidence of treatment-related adverse events in the APL-1702 group was no different from that in the placebo group, indicating good safety.
In addition, the study found that APL-1702 also demonstrated stable long-term efficacy at the extension endpoints. At 12 months, the overall response rate in the APL-1702 group reached 44.4%. Among patients who had LSIL and persistent HPV positivity at six months, 40.0% achieved response during the extension period. At the same time, HPV positivity continued to decline during the extension period.
It is also worth noting that in February 2026, Asieris announced that the marketing authorization application for APL-1702 for the treatment of patients with cervical HSIL had been accepted by the European Medicines Agency. Regarding this, Zhang Yun, Chief Medical Officer of Asieris, said that the company is committed to accelerating the global development of APL-1702, aiming to bring this transformative treatment option to women worldwide and contribute to the global strategy for cervical cancer elimination.